Assessment of Predictors for Early Resistance to Hepatitis C Virus Treatment

Noha El- Mashad¹, Hekmat El Tantawy², Eman Elsayed¹, Sherein Rkha¹, Maha Maher³, Mohammed Shokhba²

¹Department of Clinical Pathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
²Department of Zoology, Faculty of Science, Suez Canal University, Ismailia, Egypt.
³Department of Internal Medicine, Specialized Medical Hospital, Faculty of Medicine, Mansoura University, Mansoura, Egypt.

DOI: 10.4236/ojmm.2015.52012                

Abstract

The current standard of treatment for HCV is the combination of pegylated interferon (PEG-IFN) and ribavirin (RBV). Response to therapy is influenced by different factors related to virus or host characteristics. In this study we detected HCV genotype in some patients with chronic HCV infection—who received interferon plus ribavirin therapy and evaluating some risk factors in early resistance to treatment. These risk factors included age, gender, ALT& AST levels, HCV viral load & genotype. This study included 60 patients with chronic HCV infection and subjected to PEG-INF plus RBV therapy. 40 (gp I) had developed resistance after 12 weeks; while group II are the responders. on comparing patients in group I n = 40 (who developed resistance) to patients in group 2, no = 20 (responders), it has been found that the most important risk factors for developing resistance are the increased viral load of HCV-RNA, and AST.HCV-genotype as a risk factor was significantly higher among cases with genotype 1 and 4 and P value was 0.004. This was followed by ALT and AFP as risk factors with P value 0.004 for each and age with P value 0.026. However, regarding sex of the patients there was no significant difference between group I and II. In conclusion: the most frequent HCV genotype in resistant group were genotype I and IV, while in responder patient were genotype 2 & 3. The most important risk factor in this study is viral load and HCV genotype.

Keywords

HCV, Ribavirin, Pegylated Interferon, Resistance

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Strader, D.B., Wright, T., Thomas, D.L. and Seeff, L.B. (2004) American Association for the Study of Liver Diseases. Diagnosis, Management, and Treatment of Hepatitis C. Hepatology, 39, 1147-1171. http://dx.doi.org/10.1002/hep.20119
[2]	Imazeki, F., Yokosuka, O., Fukai, K., et al. (2003) Favorable Prognosis of Chronic Hepatitis C after Interferon Therapy by Long-Term Cohort Study. Hepatology, 38, 493-502. http://dx.doi.org/10.1053/jhep.2003.50329
[3]	Chevaliez, S. and Pawlotsky, J.M. (2006) Hepatitis C Virus Serologic and Virologic Testes and Clinical Diagnosis of HCV-Related Liver Disease. International Journal of Medical Sciences, 3, 35-40. http://dx.doi.org/10.7150/ijms.3.35
[4]	National Institutes of Health Consensus Development Conference Statement (2002) Management of Hepatitis C. Hepatology, 36, S3-S20.
[5]	Houck, D.R. (2006) Preclinical Evaluation of SCY-635, a Cyclophilin Inhibitor with Potent Anti-HCV Activity. Hepatology, 44, S534.
[6]	Farci, P. and Purcell, R.H. (2000) Clinical Significance of Hepatitis C Virus Genotypes and Quasispecies. Seminars in Liver Disease, 20, 10-126.
[7]	Bedossa, P. and Poynard, T. (1996) An Algorithm for the Grading of Activity in Chronic Hepatitis C. The METAVIR Cooperative Study Group. Hepatology, 24, 289-293. http://dx.doi.org/10.1002/hep.510240201
[8]	Kaplan, M.M. and Bonis, P.A. (2009) Histologic Scoring Systems for Chronic Liver Disease.
[9]	Pohjanpelto, P., Lappalainen, M., Widell, A., Asikainen, K. and Paunio, M. (1996) Hepatitis C Genotypes in Finland Determined by RFLP. Clinical and Diagnostic Virology, 7, 7-16. http://dx.doi.org/10.1016/S0928-0197(96)00242-5
[10]	Simmonds, P. (2004) Genetic Diversity and Evolution of Hepatitis C Virus—15 Years on. Journal of General Virology, 85, 3173-3188. http://dx.doi.org/10.1099/vir.0.80401-0
[11]	Levrero, M. (2003) Cellular Mechanisms of Resistance to INFS. In: Ferenci, P., Ed., EASL Postgraduate Course, Istanbul, Turkey, Kenes International, Geneva.
[12]	Alsaran, K., Sabry, A. and Shaheen, N. (2011) Pegylated Interferon Alpha-2a for Treatment of Chronic HCV Infection in Hemodialysis Patients: A Single Saudi Center Experience. International Urology and Nephrology, 43, 865-873. http://dx.doi.org/10.1007/s11255-010-9756-1
[13]	Balan, V., Schwartz, D., Wu, G.Y., Muir, A.J., Ghalib, R., Jackson, J., Keeffe, E.B., Rossaro, L., Burnett, A., Goon, B.L., Bowers, P.J. and Leitz, G.J. (2005) Erythropoietic Response to Anemia in Chronic Hepatitis C Patients Receiving Combination Pegylated Interferon/Ribavirin Erythropoietic Response to IFN/RBV Therapy. The American Journal of Gastroenterology, 100, 299-307. http://dx.doi.org/10.1111/j.1572-0241.2005.40757.x
[14]	Lavanchy, D. (2011) Evolving Epidemiology of Hepa-titis C Virus. Clinical Microbiology and Infection, 17, 107-115. http://dx.doi.org/10.1111/j.1469-0691.2010.03432.x
[15]	Saleh, O., Baiomy, A.A., El-Desouky, A., Zaghloul, H., El-Arman, M., Dahab, G.M. and Abdel-Rahman, M.S. (2013) Hepatitis C Virus Genotype Distribution in Egyptian Diabetic Patients: A Preliminary Study. Arab Journal of Gastroenterology, 14, 14-19. http://dx.doi.org/10.1016/j.ajg.2013.01.005
[16]	Abravanel, F.L., Sauné1, K.S., Barange, K., Alric, L., Moreau, J., Desmorat, P., Vinel, J.P. and Izopet, J. (2004) Hepatitis C Virus Genotype 5: Epidemiological Characteristics and Sensitivity to Combination Therapy with Interferon-α Plus Ribavirin. The Journal of Infectious Diseases, 189, 1397-1400. http://dx.doi.org/10.1086/382544
[17]	Hui, C.K., Yuen, M.F., Sablon, E., Chan, A.O., Wong, B.C. and Lai, C.L. (2003) Interferon and Ribavirin Therapy for Chronic Hepatitis C Virus Genotype 6: A Comparison with Genotype 1. The Journal of Infectious Diseases, 187, 1071-1074. http://dx.doi.org/10.1086/368217
[18]	Chevaliez, S. (2013) New Markers for Diagnosis and Management of Chronic Hepatitis C Virus Infection. Annals of Gastroenterology, 26, 98-99.
[19]	DeLeuw, P., Sarraz, C. and Zeuzem, S. (2011) How to Use Virological Tools for the Optimal Management of Chronic Hepatitis C. Liver International, 31, 3-12. http://dx.doi.org/10.1111/j.1478-3231.2010.02398.x
[20]	Hamidi, F.M., Samarbaf, Z.A., Makvandi, M. and Hajiani, E. (2009) Determination of HCV Genotypes among Chronic Hepatic Patients in Ahvaz. Iranian Journal of Virology, 3, 12-16.
[21]	Pockros, P.J., Hamze, F.M., Martin, P., Lentz, E., Zhou, X., Govindarajan, S. and Lok, A.S. (2010) Histologic Outcomes in Hepatitis C—Infected Patients with Varying Degrees of Virologic Response to Interferon-Based Treatments. Hepatology, 52, 1193-1200. http://dx.doi.org/10.1002/hep.23809
[22]	Jármay, K., Lonovics, J. and Schaff, Z. (2003) Clinicopathologic Observations on Chronic Hepatitis C Therapy with Interferon-Alpha. Orvosi Hetilap, 144, 1325-1330.
[23]	Nachnani, J.S., Gidwani, R., Sadeddin, E., Clarkston, W.K., Fiorella, R. and Alba, L.M. (2007) Clinical Pathological Predictors to Predict Sustained Viral Response Rates in Patients with Chronic Hepatitis C Infection. Indian Journal of Gastroenterology, 26, 279-282.
[24]	Hung, C.H., Lee, C.M., Lu, S.N., Wang, J.H., Chen, C.H., Hu, T.H., Kee, K.M., Chang, K.C., Tseng, P.L., Yen, Y.H. and Changchien, C.S. (2006) Anemia Associated with Antiviral Therapy in Chronic Hepatitis C: Incidence, Risk Factors, and Impact on Treatment Response. Liver International, 26, 1079-1086. http://dx.doi.org/10.1111/j.1478-3231.2006.01354.x
[25]	Zeuzem, S., Feinman, S.V., Rasenack, J., et al. (2000) Peginterferon Alfa-2a in Patients with Chronic Hepatitis C. The New England Journal of Medicine, 343, 1666-1672. http://dx.doi.org/10.1056/NEJM200012073432301
[26]	Kau, A., Vermehren, J. and Sarrazin, C. (2008) Treatment Predictors of a Sustained Virologic Response in Hepatitis B and C. Journal of Hepatology, 49, 634-651. http://dx.doi.org/10.1016/j.jhep.2008.07.013